Novo Nordisk acquires Dicerna for USD 3.3bn

Novo Nordisk is acquiring the US-based biotech business Dicerna for USD 3.3bn. The two companies are already collaborating within NASH, type 2 diabetes and obesity, in addition to rare diseases.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

On Thursday, Novo Nordisk announces in a press release that it is acquiring the US-based firm Dicerna, which has been a frequent collaborator of the Danish pharmaceutical company since 2019.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading